Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Executive Summary
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
You may also be interested in...
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Duragesic Risk Management Plan Under “Discussion”; New Warnings Added
Johnson & Johnson/Alza and FDA are discussing the creation of a risk management program for Duragesic, the agency said in a Feb. 4 letter approving labeling changes for the fentanyl transdermal system